Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Update

Synaptogenix, Inc. (NASDAQ:SNPX) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 33,700 shares, an increase of 183.2% from the March 31st total of 11,900 shares. Based on an average daily volume of 48,500 shares, the short-interest ratio is currently 0.7 days. Currently, 3.2% of the shares of the stock are sold short.

Synaptogenix Stock Performance

Shares of NASDAQ:SNPX traded up $0.12 during trading hours on Friday, hitting $4.53. 6,923 shares of the company’s stock traded hands, compared to its average volume of 42,709. Synaptogenix has a 52 week low of $3.53 and a 52 week high of $47.00. The company’s fifty day simple moving average is $4.79 and its two-hundred day simple moving average is $5.89.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.